evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4 questions · 4 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 25%Low 3 · 75%Moderate 0 · 0%High 0 · 0%

ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) vs placebo

Adverse effects ‐ any adverse effect · 18 to 85 year‐old patients with schizophrenia, schizoaffective disorder, mood disorder, or gastrointestinal disorder +…

ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) showed no clear difference in adverse effects ‐ any adverse effect compared with PLACEBO (low certainty).

1 finding from 1 review

ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS vs placebo

Adverse effects ‐ any adverse effect · female and male 59‐80 (mean) years old patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS changes adverse effects ‐ any adverse effect compared with PLACEBO (very low certainty).

1 finding from 1 review

POLYPEPTIDE ‐ CERULETIDE vs placebo

Adverse effects ‐ any adverse effect · female and male 55‐59 year old (mean) patients with various psychiatric conditions and antipsychotic‐induced tardive dyskinesia

POLYPEPTIDE ‐ CERULETIDE showed no clear difference in adverse effects ‐ any adverse effect compared with PLACEBO (low certainty).

1 finding from 1 review